
Cannabis Users Face Growing 'Scromiting' Health Concern
Increasing cases of cannabinoid hyperemesis syndrome spark alarm
Emergency room visits for Cannabinoid Hyperemesis Syndrome—a condition causing severe vomiting in regular cannabis users—have increased in states with legal marijuana, according to recent medical data.
The condition, nicknamed "scromiting" for the screaming that sometimes accompanies intense nausea, remains rare but appears to be becoming more common as cannabis use increases and products become more potent.
"We're seeing more cases as the average THC content in products rises," said Dr. Kenneth Taylor, a cannabinoid researcher. "Patients often don't associate their symptoms with cannabis because it's counterintuitive."
What Is CHS?
Cannabinoid Hyperemesis Syndrome causes cyclical episodes of severe nausea and vomiting in some long-term cannabis users. The symptoms are paradoxical because cannabis is typically used to treat nausea, not cause it.
Many patients report temporary relief from hot showers or baths, a distinctive symptom that helps doctors diagnose the condition. But the only proven long-term solution is stopping cannabis use entirely.
The exact mechanism causing CHS isn't fully understood. Researchers believe it may involve how cannabinoids interact with receptors in the digestive system over time, though high-potency products appear to increase risk.
Rising Incidence
Emergency departments in Colorado, California, and other legal states have reported increases in CHS cases since recreational legalization. The rise correlates with increased cannabis use and the availability of high-THC concentrates and edibles.
Many cases likely go undiagnosed because patients don't mention their cannabis use to doctors, or physicians don't consider CHS as a possible diagnosis. As awareness grows among medical professionals, diagnosis rates are expected to increase further.
Public Health Implications
The condition highlights knowledge gaps about cannabis health effects—particularly around chronic, high-dose use of potent products. Most cannabis research has focused on occasional or moderate use of traditional flower products.
For the cannabis industry, CHS represents a consumer education challenge. Companies and regulators will need to develop guidance around product potency, consumption patterns, and potential risks—similar to alcohol industry competition practices around responsible consumption.
This article is based on original reporting by Boston Herald.
Original Source
This article is based on reporting from Boston Herald.
Read the original articleOriginal title: "Screaming + vomiting: ‘Scromiting’ is the mysterious cannabis syndrome becoming more common"
Related Topics
Related Stories
Medical CannabisLegal Cannabis Linked to Drop in Opioid Deaths, New Analysis Finds
New analysis shows states with legal cannabis markets experiencing measurable drops in opioid overdose deaths, adding evidence for marijuana as harm reduction tool.
New Study Links Cannabis to Pain Relief in Arthritis Patients
Research tracking 128 patients with fibromyalgia and arthritis found cannabis products—both THC and CBD formulations—provided measurable pain relief, adding clinical evidence for medical cannabis in chronic pain treatment.
Hemp Plastic Emerges as Viable Alternative to Petroleum Packaging
New research shows hemp-based plastics can match petroleum-derived packaging in durability while offering biodegradability, potentially disrupting the $370 billion global plastics market.
More from Alex Morgan
View all articles
Social Equity Architect Calls Program a 'Trap' for Black Founders
Hemp Industry Sues DEA Over HHC Ban in Federal Court Challenge

